Your browser doesn't support javascript.
loading
Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.
McGrail, D J; Pilié, P G; Rashid, N U; Voorwerk, L; Slagter, M; Kok, M; Jonasch, E; Khasraw, M; Heimberger, A B; Ueno, N T; Ferrarotto, R; Chang, J T; Lin, S-Y.
Affiliation
  • McGrail DJ; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: djmcgrail@mdanderson.org.
  • Pilié PG; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Rashid NU; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, USA.
  • Voorwerk L; Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Slagter M; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
  • Kok M; Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Jonasch E; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Khasraw M; The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, USA.
  • Heimberger AB; Department of Neurological Surgery, Northwestern University, Chicago, USA; Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago.
  • Ueno NT; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Ferrarotto R; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Chang JT; Department of Integrative Biology and Pharmacology, The University of Texas Health Sciences Center at Houston, Houston, USA; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Lin SY; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: sylin@mdanderson.org.
Ann Oncol ; 32(9): 1194-1197, 2021 09.
Article in En | MEDLINE | ID: mdl-34166757
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Neoplasms Type of study: Prevalence_studies / Risk_factors_studies Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2021 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Neoplasms Type of study: Prevalence_studies / Risk_factors_studies Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2021 Document type: Article